Kyverna Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
KYTX$4.88+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $32,194 | $124,093 |
| Available-for-sale marketable securities | 204,252 | 155,160 |
| Prepaid expenses and other current assets | 5,280 | 3,700 |
| Total current assets | 241,726 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,343 | 1,546 |
| Operating lease right-of-use assets | 8,192 | 3,568 |
| Finance lease right-of-use assets | 198 | 305 |
| Other non-current assets | 5,014 | 4,903 |
| Total assets | $257,024 | $293,826 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $11,603 | $5,306 |
| Accrued compensation | 3,114 | 9,990 |
| Accrued license expense – related party | 3,750 | 3,750 |
| Other accrued expenses and current liabilities | 9,222 | 13,472 |
| Operating lease liabilities, short-term portion | 1,764 | 3,662 |
| Finance lease liabilities, short-term portion | 221 | 307 |
| Total current liabilities | 29,674 | 36,487 |
| Operating lease liabilities, net of short-term portion | 6,958 | 320 |
| Term loan | 24,812 | 24,743 |
| Total liabilities | 61,444 | 61,550 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 60,532,500 and 60,389,893 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 1 | 1 |
| Additional paid-in capital | 660,230 | 657,005 |
| Accumulated other comprehensive income/(loss) | (96) | 97 |
| Accumulated deficit | (464,555) | (424,827) |
| Total stockholders’ equity | 195,580 | 232,276 |
| Total liabilities and stockholders’ equity | $257,024 | $293,826 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.